Bisphosphonates reduce peri-prosthetic bone loss in the short term after total hip replacement but the mid- and longer term effects are not known. The aims of this randomised trial were to examine the effect of a single dose of 90 mg of pamidronate on the clinical and radiological outcome and peri-prosthetic bone mineral density in 50 patients (56 hips) over a five-year period, following total ...

The aim of the present study was to examine the potential antitumor activity of lovastatin and other statins together with pamidronate, a second generation bisphosphonate (BP), against tumor cell lines. Cytostatic/cytotoxic effects were measured using crystal violet assay. Regulation of the cell cycle and induction of apoptosis were evaluated using flow cytometry and Western blotting, migration...

Bone turnover, bone loss and fracture risk increase after liver transplantation. It has been postulated that peri-operative administration of a bisphosphonate might prevent bone loss and reduce fracture rate. We studied the effects of a single pre-operative dose of pamidronate on biochemical parameters of skeletal metabolism in the first month after liver transplantation. In a randomized, singl...

Over the past 20 years, orally administered biphosphonates have been used extensively in the management of a number of common skeletal disorders of different etiology. Recently, in clinical practice, in a number of cases in whom oral therapy is insufficient or contraindicated, intravenous administration of pamidronate presents an alternative therapeutic option. In order to investigate the clini...

BACKGROUND Bisphosphonates (BP) increase bone mass in patients with rheumatoid arthritis and are effective in the prevention and treatment of steroid-induced osteoporosis. However, little is known about their direct effects on chondrocytes. OBJECTIVES To study the influence of BP on articular chondrocytes in vitro and to investigate whether BP can prevent steroid-induced apoptosis of articula...

INTRODUCTION Kidney transplantation is associated with rapid loss of bone mineral density (BMD) in the first months after transplantation. The effect of pamidronate on bone loss after transplantation was evaluated in a randomized controlled trial. MATERIALS AND METHODS Forty patients were enrolled in this study (16 in the pamidronate group and 24 in the control group). Pamidrinate was adminis...

Recently, there has been much controversy over whether patients with prostate cancer should be treated with bisphosphonates not only to decrease pain, but to prevent metastasis. This brief review summarizes the known data in this area. The main points made in the discussion are highlighted in previews appearing at the beginning of each section of the article. Preview: Bisphosphonates inhibit bo...

Bisphosphonates are the mainstay of medical therapy in the fracturing child with osteoporosis. The majority of the data in children pertains to intravenous pamidronate use in children and adolescents with osteogenesis imperfecta (OI), where pamidronate has been associated with improvements in bone mineral density, cortical thickness, vertebral shape, pain, mobility and height [1]. Sideeffects o...

Eighteen osteoporotic (Z-score at or below 2.5) nonambulatory children with cerebral palsy or a neuromuscular disorder received cyclic intravenous administration of pamidronate. One year after treatment, bone densitometry showed an improvement in all patients: a mean increase of 13% +/- 15% standard deviation (SD) (p < 10(-5)) on the global data, and a mean increase of 27% +/- 15% (p < 10(-5)) ...

We present here successful treatment with bisphosphonate pamidronate of a 54-yearold patient with advanced ovarian cancer and humoral hypercalcemia of malignancy, followed by cytoreductive surgery and postoperative chemotherapy. Concentration of serum calcium increased to 16.8 mg/dL and parathyroid hormone-related protein (PTHrP)-intact was remarkably elevated. Interestingly, the 1,25-dihydroxy...